On May 28, 2025, Spero Therapeutics announced that its Phase 3 trial for tebipenem HBr, a treatment for complicated urinary tract infections, successfully met its main goal and will stop early for effectiveness. The trial involved 1,690 patients and found the treatment comparable in efficacy to a current standard, prompting plans for regulatory filing in late 2025.